The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Coronary interventions

Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)

EuroIntervention 2019;15:e990-e998. DOI: 10.4244/EIJ-D-19-00539

1. AOU Maggiore della Carità, Eastern Piedmont University, Novara, Italy; 2. Radboud University Medical Center, Nijmegen, the Netherlands; 3. Jessa Ziekenhuis, Hasselt, Belgium; 4. Maastricht University Medical Center, Maastricht, the Netherlands; 5. Zuyderland Atrium Medical Center, Heerlen, the Netherlands; 6. Queen Elizabeth II, Sabah, Malaysia; 7. Jeroen Bosch Ziekenhuis, 's Hertogenbosch, the Netherlands; 8. University Malaya, Kuala Lumpur, Malaysia; 9. National Heart Institute, Kuala Lumpur, Malaysia; 10. Diagram BV, Zwolle, the Netherlands; 11. Isala Hospital, Zwolle, The Netherlands

Aims: The optimal duration of DAPT in ACS patients treated with DES is still unclear. Therefore, the aim of the current study was to investigate a short versus a standard 12-month DAPT regimen in ACS patients undergoing new-generation DES implantation.

Methods and results: REDUCE was a prospective, open-label, multicentre, investigator-initiated study that randomised 1,496 ACS patients after treatment with the COMBO stent to either three (n=751) or 12 months (n=745) of DAPT. The primary study endpoint was a composite of all-cause mortality, myocardial infarction, stent thrombosis, stroke, target vessel revascularisation and bleeding at 12 months. No difference was observed in the demographic and clinical characteristics between the two groups, except for gender (p=0.01). At one-year follow-up, non-inferiority of three- versus 12-month DAPT in the primary endpoint was met (8.2% vs 8.4%, pnon-inferiority<0.001). The similar outcome between the two groups was confirmed at two-year follow-up (11.6% vs 12.1%, p=0.76), with no significant difference in overall mortality (3.1% vs 2.2%, p=0.27), cardiac mortality (1.8% vs 1.1%, p=0.28), stent thrombosis (1.6% vs 0.8%, p=0.16) and major bleeding (3.3% vs 4.0%, p=0.46).

Conclusions: The results show that, among ACS patients treated with the COMBO stent, three months is non-inferior to 12 months of DAPT. However, given the numerically higher rates of mortality and ST in the three-month DAPT group, one-year DAPT should still be recommended in ACS until more information becomes available. A three-month DAPT strategy should be considered only if clinically mandated.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Graft patency after FFR-guided versus angiography-guided coronary artery bypass grafting: the GRAFFITI trial